Study of Jitongning Tablet to Treat Spondyloarthritis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

238 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-06-11

Study Completion Date

2021-08-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is to investigate the efficacy and safety of Jitongning Tablet in improving joint function and pain symptoms in active axial spondyloarthritis (SpA) patients and to explore the optimal dosage.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of Comparing Overall Improvement of Patients With Spondyloarthritis Treated With Jitongning Tablets and Placebo

NCT06000956

Ankylosing Spondylitis

RECRUITING PHASE3

A Study to Evaluate the Efficacy and Safety of 608 in Adult Subjects With Active Ankylosing Spondylitis(AS)

NCT07261644

Ankylosing Spondylitis

RECRUITING PHASE3

Multi-omics Study and Drug Intervention Study of Spondyloarthritis

NCT05494203

Spondylarthritis

UNKNOWN

A Study to Evaluate the Efficacy and Safty of 608 in Patients With Non- Radiographic Axial Spondyloarthritis (Nr-axSpA)

NCT07349329

Axial Spondyloarthritis, Non-Radiographic

NOT_YET_RECRUITING PHASE3

A Study of Ixekizumab (LY2439821) in Chinese Participants With Radiographic Axial Spondyloarthritis

NCT04285229

Spondyloarthritis

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Jitongning Tablet is a kind of traditional Chinese medicine(TCM), consists of Cortex Eucommiae, Duhuo(Radix Angelicae Pubescentis), Zhichuanwu(Radix Aconiti) , Rhizoma Corydalis, Radix Paeoniae Rubra, Radix Puerariae and Radix Glycyrrhizae. This study is being conducted to evaluate the efficacy and safety of Jitongning Tablet in patients with active axial spondyloarthritis (SpA) (Syndrome Of Kidney Yang Deficiency and Biood Stasis Stagnation), when compared with placebo and to explore the optimal dosage.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Spondyloarthritis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Jitongning tablet High dose group

Jitongning tablet,3tablets,bid,po

Group Type EXPERIMENTAL

Jitongning tablet(High-dose )

Intervention Type DRUG

Jitongning tablet,3tablets,bid,treat 12 weeks

Jitongning tablet Low dose group

Jitongning tablet,2tablets,bid,po Jitongning tablet placebo,1tablet,bid,po

Group Type EXPERIMENTAL

Jitongning tablet(Low-dose )

Intervention Type DRUG

Jitongning tablet,2tablets,bid,treat 12 weeks Jitongning tablet placebo,1tablet,bid,treat 12 weeks

Placebo Comparator controlled group

Placebo Comparator: Jitongning tablet placebo,3tablets,bid,po

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Jitongning tablet placebo,3tablets,bid,treat 12 weeks

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Jitongning tablet(High-dose )

Jitongning tablet,3tablets,bid,treat 12 weeks

Intervention Type DRUG

Jitongning tablet(Low-dose )

Jitongning tablet,2tablets,bid,treat 12 weeks Jitongning tablet placebo,1tablet,bid,treat 12 weeks

Intervention Type DRUG

Placebo

Jitongning tablet placebo,3tablets,bid,treat 12 weeks

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Jitongning tablet,3tablets Jitongning tablet,2tablets,Jitongning tablet placebo,1tablet, Jitongning tablet placebo,3tablets

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Men or women aged 18 to 65 years old (including 18 and 65) ;
* Meeting the diagnostic criteria for active axial SpA according to the the ASAS classification 2009, defined as satisfied 2 of the following:

1. BASDAI score ≥ 4;
2. In the assessment of pain numerical rating scale (NRS), spine pain NRS ≥ 4;
* Meeting the standard of TCM syndrome diagnosis for kidney yang deficiency and biood stasis stagnating syndrome;
* Sacroiliac arthritis of CT categories I(A)\~Ⅲ(B) (including I(A) and Ⅲ(B));
* Human leukocyte antigen B27 (HLA-B27) is positive;
* C-reactive protein (CRP)/hypersensitive C-reactive protein (hsCRP) and/or erythrocyte sedimentation rate raised;
* Voluntary signing of informed consent.

Exclusion Criteria

* Those who use NSAIDs in the first 2 weeks of randomization;
* In the first 4 weeks of randomization, take disease-modifying antirheumatic Chinese herbal medicine or Chemical drugs (such as sulfasalazine ,methotrexate, leflunomide, Chloroquine, Total glycosides of Tripterygium, Cyclophosphamide, Azathioprine, etc),opioid analgesics(Methadone, Morphine, etc.) ,systemic glucocorticoid therapy;
* In the first 3 months of randomization, take biological agents that have been used for spinal arthritis;
* Those who have undergone spinal surgery or joint surgery within 8 weeks before randomization;
* Patients who received intra-articular injection, spinal or paravertebral injection of corticosteroids within the first 6 months of randomization;
* The spine is completely stiff (fused);
* Any Other rheumatic immune system diseases or immunodeficiency syndromes such as ulcerative colitis, psoriasis, uveitis, etc.
* Those who have a fertility requirement within 6 months;
* Women during pregnancy and lactation;
* Suspected or indeed drug use, substance abuse, alcoholism;
* In the first 3 months of randomization, take the test or in progress;
* Serious cardiovascular, Liver , kidney, brain, mental, neurological disorders that affect informed consent and/or adverse event expression or observation;
* Abnormal liver function(the AST or ALT value is above the upper limit of the normal); Abnormal renal function (serum creatinine is above the upper limit of normal);
* Due to other circumstances, the investigator considered it inappropriate for the participants.

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No